{"id":"NCT03343704","sponsor":"Boehringer Ingelheim","briefTitle":"This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding","officialTitle":"A Phase III, Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of Idarucizumab (BI 655075) in Patients Treated With Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-26","primaryCompletion":"2020-07-02","completion":"2020-07-02","firstPosted":"2017-11-17","resultsPosted":"2021-08-20","lastUpdate":"2025-02-25"},"enrollment":19,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemorrhage"],"interventions":[{"type":"DRUG","name":"Idarucizumab","otherNames":["PRAXBIND, Praxbind, Prizbind"]}],"arms":[{"label":"Group A - patients with uncontrolled or life-threatening bleeding","type":"EXPERIMENTAL"},{"label":"Group B - patients not bleeding but requiring emergency surgery or invasive procedure","type":"EXPERIMENTAL"}],"summary":"The primary objective is to demonstrate reversal of the anticoagulant effect of dabigatran in patients treated with dabigatran etexilate who have uncontrolled or life-threatening bleeding requiring urgent intervention, and in patients treated with dabigatran etexilate who require emergency surgery or other invasive procedure.\n\nThe secondary objectives are to assess the reduction or cessation of bleeding, evaluate the clinical outcomes, safety and the pharmacokinetics of dabigatran in the presence of idarucizumab.","primaryOutcome":{"measure":"Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of Ecarin Clotting Time","timeFrame":"From the end of first infusion up to 4 hours after the completion of the second infusion on Day 1 of the treatment period.","effectByArm":[{"arm":"Group A - Patients With Uncontrolled or Life-threatening Bleeding","deltaMin":100,"sd":null},{"arm":"Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure","deltaMin":100,"sd":null},{"arm":"Total","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":13,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["http://www.mystudywindow.com/"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":13},"commonTop":["Anaemia","Hypoalbuminaemia","Constipation","Diarrhoea","Infection"]}}